person · Reporting owner

BARASCH RICHARD A

Disclosed activity across 4 companies

Tapewire entity: 76540
SEC CIK: 0001076341

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
AdaptHealth Corp.AHCO · Entity 5183	Director	June 18, 2024	June 24, 2024
CareMax, Inc.CMAX · Entity 87127	Director	June 08, 2021	June 10, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

AdaptHealth Corp.

Report date June 18, 2024 · Filed June 24, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	438,355	Reported balance After 2024-06-18 transaction · row 1 1 source row Row 1 · 2024-06-18 · Tax withholding · Disposed 3,559 · Balance 438,355 F1: The reporting person surrendered 3,559 shares to satisfy tax withholding liabilities in connection with the vesting of a previously issued restricted stock grant.

Filing footnotes · ownership attribution and instrument terms

F1: The reporting person surrendered 3,559 shares to satisfy tax withholding liabilities in connection with the vesting of a previously issued restricted stock grant.

CareMax, Inc.

Report date June 08, 2021 · Filed June 10, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	50,000	Reported balance After 2021-06-08 transaction · row 1 1 source row Row 1 · 2021-06-08 · Conversion · Acquired 50,000 · Balance 50,000 F1: On June 8, 2021, Deerfield Healthcare Technology Acquisitions Corp. consummated its business combination (the "Business Combination") with CareMax Medical Group, LLC and IMC Medical Group Holdings, LLC, with the combined company being renamed "CareMax, Inc." In connection with the consummation of the Business Combination, the shares of Class B common stock automatically converted into shares of Class A common stock on a one-for-one basis.
Class B Common StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2021-06-08 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-06-08 · Conversion · Disposed 50,000 · Balance 0 F1: On June 8, 2021, Deerfield Healthcare Technology Acquisitions Corp. consummated its business combination (the "Business Combination") with CareMax Medical Group, LLC and IMC Medical Group Holdings, LLC, with the combined company being renamed "CareMax, Inc." In connection with the consummation of the Business Combination, the shares of Class B common stock automatically converted into shares of Class A common stock on a one-for-one basis.

Filing footnotes · ownership attribution and instrument terms

F1: On June 8, 2021, Deerfield Healthcare Technology Acquisitions Corp. consummated its business combination (the "Business Combination") with CareMax Medical Group, LLC and IMC Medical Group Holdings, LLC, with the combined company being renamed "CareMax, Inc." In connection with the consummation of the Business Combination, the shares of Class B common stock automatically converted into shares of Class A common stock on a one-for-one basis.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Starling Oncology, Inc.

Report date August 12, 2025 · Filed August 14, 2025

Section 16 reporting ended · disclosed 2025-08-14. Current position is not established by this disclosure.

No balance rows disclosed in this filing.

UNIVERSAL AMERICAN CORP.

Report date April 28, 2017 · Filed May 02, 2017

Section 16 reporting ended · disclosed 2017-05-02. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2017-04-28 transaction · row 1 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 1 · 2017-04-28 · Disposition to issuer · Disposed 1,664,791 · Balance 0 F1: Pursuant to that certain Agreement and Plan of Merger, dated as of November 17, 2016 (the "Merger Agreement"), by and among Universal American Corp. (the "Company"), WellCare Health Plans, Inc. and Wind Merger Sub, Inc., at the Effective Time (as defined in the Merger Agreement) (the "Effective Time"), each of these shares of the Company's common stock was cancelled and converted into the right to receive an amount in cash equal to the per share merger consideration of $10.00 (the "Per Share Merger Consideration").
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2017-04-28 transaction · row 2 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 2 · 2017-04-28 · Disposition to issuer · Disposed 423,468 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each of these unvested shares of the Company's common stock was cancelled and converted into the right to receive an amount in cash equal to the Per Share Merger Consideration, subject to conditions set forth in the Merger Agreement.
Common StockSEC Table I · non-derivative	IndirectBy Wife	Reported balance After 2017-04-28 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2017-04-28 · Disposition to issuer · Disposed 222,077 · Balance 0 F1: Pursuant to that certain Agreement and Plan of Merger, dated as of November 17, 2016 (the "Merger Agreement"), by and among Universal American Corp. (the "Company"), WellCare Health Plans, Inc. and Wind Merger Sub, Inc., at the Effective Time (as defined in the Merger Agreement) (the "Effective Time"), each of these shares of the Company's common stock was cancelled and converted into the right to receive an amount in cash equal to the per share merger consideration of $10.00 (the "Per Share Merger Consideration").
Common StockSEC Table I · non-derivative	IndirectBy Son (Benjamin)	Reported balance After 2017-04-28 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2017-04-28 · Disposition to issuer · Disposed 28,180 · Balance 0 F1: Pursuant to that certain Agreement and Plan of Merger, dated as of November 17, 2016 (the "Merger Agreement"), by and among Universal American Corp. (the "Company"), WellCare Health Plans, Inc. and Wind Merger Sub, Inc., at the Effective Time (as defined in the Merger Agreement) (the "Effective Time"), each of these shares of the Company's common stock was cancelled and converted into the right to receive an amount in cash equal to the per share merger consideration of $10.00 (the "Per Share Merger Consideration").
Common StockSEC Table I · non-derivative	IndirectBy Daughter (Natalie)	Reported balance After 2017-04-28 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 5 · 2017-04-28 · Disposition to issuer · Disposed 23,080 · Balance 0 F1: Pursuant to that certain Agreement and Plan of Merger, dated as of November 17, 2016 (the "Merger Agreement"), by and among Universal American Corp. (the "Company"), WellCare Health Plans, Inc. and Wind Merger Sub, Inc., at the Effective Time (as defined in the Merger Agreement) (the "Effective Time"), each of these shares of the Company's common stock was cancelled and converted into the right to receive an amount in cash equal to the per share merger consideration of $10.00 (the "Per Share Merger Consideration").
Common StockSEC Table I · non-derivative	IndirectBy Daughter (Emily)	Reported balance After 2017-04-28 transaction · row 6 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 6 · 2017-04-28 · Disposition to issuer · Disposed 30,124 · Balance 0 F1: Pursuant to that certain Agreement and Plan of Merger, dated as of November 17, 2016 (the "Merger Agreement"), by and among Universal American Corp. (the "Company"), WellCare Health Plans, Inc. and Wind Merger Sub, Inc., at the Effective Time (as defined in the Merger Agreement) (the "Effective Time"), each of these shares of the Company's common stock was cancelled and converted into the right to receive an amount in cash equal to the per share merger consideration of $10.00 (the "Per Share Merger Consideration").
Common StockSEC Table I · non-derivative	IndirectTara Acquisition LLC	Reported balance After 2017-04-28 transaction · row 7 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 7 · 2017-04-28 · Disposition to issuer · Disposed 215,835 · Balance 0 F1: Pursuant to that certain Agreement and Plan of Merger, dated as of November 17, 2016 (the "Merger Agreement"), by and among Universal American Corp. (the "Company"), WellCare Health Plans, Inc. and Wind Merger Sub, Inc., at the Effective Time (as defined in the Merger Agreement) (the "Effective Time"), each of these shares of the Company's common stock was cancelled and converted into the right to receive an amount in cash equal to the per share merger consideration of $10.00 (the "Per Share Merger Consideration").
Common StockSEC Table I · non-derivative	IndirectHB Family Trust #1	Reported balance After 2017-04-28 transaction · row 8 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 8 · 2017-04-28 · Disposition to issuer · Disposed 33,872 · Balance 0 F1: Pursuant to that certain Agreement and Plan of Merger, dated as of November 17, 2016 (the "Merger Agreement"), by and among Universal American Corp. (the "Company"), WellCare Health Plans, Inc. and Wind Merger Sub, Inc., at the Effective Time (as defined in the Merger Agreement) (the "Effective Time"), each of these shares of the Company's common stock was cancelled and converted into the right to receive an amount in cash equal to the per share merger consideration of $10.00 (the "Per Share Merger Consideration").
Common StockSEC Table I · non-derivative	IndirectBarasch Family Trust #3	Reported balance After 2017-04-28 transaction · row 9 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 9 · 2017-04-28 · Disposition to issuer · Disposed 494,400 · Balance 0 F1: Pursuant to that certain Agreement and Plan of Merger, dated as of November 17, 2016 (the "Merger Agreement"), by and among Universal American Corp. (the "Company"), WellCare Health Plans, Inc. and Wind Merger Sub, Inc., at the Effective Time (as defined in the Merger Agreement) (the "Effective Time"), each of these shares of the Company's common stock was cancelled and converted into the right to receive an amount in cash equal to the per share merger consideration of $10.00 (the "Per Share Merger Consideration").
Common StockSEC Table I · non-derivative	IndirectBarasch Family Trust #1	Reported balance After 2017-04-28 transaction · row 10 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 10 · 2017-04-28 · Disposition to issuer · Disposed 220,768 · Balance 0 F1: Pursuant to that certain Agreement and Plan of Merger, dated as of November 17, 2016 (the "Merger Agreement"), by and among Universal American Corp. (the "Company"), WellCare Health Plans, Inc. and Wind Merger Sub, Inc., at the Effective Time (as defined in the Merger Agreement) (the "Effective Time"), each of these shares of the Company's common stock was cancelled and converted into the right to receive an amount in cash equal to the per share merger consideration of $10.00 (the "Per Share Merger Consideration").
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.18	Direct	Reported balance After 2017-04-28 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2017-04-28 · Disposition to issuer · Disposed 300,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each of these stock options was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Per Share Merger Consideration over the per share exercise price of such stock option multiplied by the aggregate number of shares of common stock in respect of such stock option immediately before the Effective Time.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.05	Direct	Reported balance After 2017-04-28 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2017-04-28 · Disposition to issuer · Disposed 234,597 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each of these stock options was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Per Share Merger Consideration over the per share exercise price of such stock option multiplied by the aggregate number of shares of common stock in respect of such stock option immediately before the Effective Time.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.05	Direct	Reported balance After 2017-04-28 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2017-04-28 · Disposition to issuer · Disposed 78,200 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each of these unvested stock options was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Per Share Merger Consideration over the per share exercise price of such stock option multiplied by the aggregate number of shares of common stock in respect of such stock option immediately before the Effective Time, subject to conditions set forth in the Merger Agreement.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.41	Direct	Reported balance After 2017-04-28 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2017-04-28 · Disposition to issuer · Disposed 30,784 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each of these stock options was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Per Share Merger Consideration over the per share exercise price of such stock option multiplied by the aggregate number of shares of common stock in respect of such stock option immediately before the Effective Time.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.41	Direct	Reported balance After 2017-04-28 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2017-04-28 · Disposition to issuer · Disposed 30,784 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each of these unvested stock options was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Per Share Merger Consideration over the per share exercise price of such stock option multiplied by the aggregate number of shares of common stock in respect of such stock option immediately before the Effective Time, subject to conditions set forth in the Merger Agreement.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.09	Direct	Reported balance After 2017-04-28 transaction · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · 2017-04-28 · Disposition to issuer · Disposed 21,565 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each of these stock options was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Per Share Merger Consideration over the per share exercise price of such stock option multiplied by the aggregate number of shares of common stock in respect of such stock option immediately before the Effective Time.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.09	Direct	Reported balance After 2017-04-28 transaction · row 17 Instrument identity requires review; Table II rows are not merged. 1 source row Row 17 · 2017-04-28 · Disposition to issuer · Disposed 64,696 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each of these unvested stock options was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Per Share Merger Consideration over the per share exercise price of such stock option multiplied by the aggregate number of shares of common stock in respect of such stock option immediately before the Effective Time, subject to conditions set forth in the Merger Agreement.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.41	Direct	Reported balance After 2017-04-28 transaction · row 18 Instrument identity requires review; Table II rows are not merged. 1 source row Row 18 · 2017-04-28 · Disposition to issuer · Disposed 61,568 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each of these unvested stock options was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Per Share Merger Consideration over the per share exercise price of such stock option multiplied by the aggregate number of shares of common stock in respect of such stock option immediately before the Effective Time, subject to conditions set forth in the Merger Agreement.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.09	Direct	Reported balance After 2017-04-28 transaction · row 19 Instrument identity requires review; Table II rows are not merged. 1 source row Row 19 · 2017-04-28 · Disposition to issuer · Disposed 21,565 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each of these stock options was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Per Share Merger Consideration over the per share exercise price of such stock option multiplied by the aggregate number of shares of common stock in respect of such stock option immediately before the Effective Time.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.09	Direct	Reported balance After 2017-04-28 transaction · row 20 Instrument identity requires review; Table II rows are not merged. 1 source row Row 20 · 2017-04-28 · Disposition to issuer · Disposed 64,696 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each of these unvested stock options was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Per Share Merger Consideration over the per share exercise price of such stock option multiplied by the aggregate number of shares of common stock in respect of such stock option immediately before the Effective Time, subject to conditions set forth in the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to that certain Agreement and Plan of Merger, dated as of November 17, 2016 (the "Merger Agreement"), by and among Universal American Corp. (the "Company"), WellCare Health Plans, Inc. and Wind Merger Sub, Inc., at the Effective Time (as defined in the Merger Agreement) (the "Effective Time"), each of these shares of the Company's common stock was cancelled and converted into the right to receive an amount in cash equal to the per share merger consideration of $10.00 (the "Per Share Merger Consideration").

F2: Pursuant to the Merger Agreement, at the Effective Time, each of these unvested shares of the Company's common stock was cancelled and converted into the right to receive an amount in cash equal to the Per Share Merger Consideration, subject to conditions set forth in the Merger Agreement.

F3: Pursuant to the Merger Agreement, at the Effective Time, each of these stock options was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Per Share Merger Consideration over the per share exercise price of such stock option multiplied by the aggregate number of shares of common stock in respect of such stock option immediately before the Effective Time.

F4: Pursuant to the Merger Agreement, at the Effective Time, each of these unvested stock options was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Per Share Merger Consideration over the per share exercise price of such stock option multiplied by the aggregate number of shares of common stock in respect of such stock option immediately before the Effective Time, subject to conditions set forth in the Merger Agreement.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 24, 2025 Filed Jul 28, 2025 21:08 UTC	Starling Oncology, Inc. TOI · Entity 5327	OtherCommon Stock	287,756	$0.00	$0.00	Disclosure SEC source: 0000935836-25-000475 · ownership.xml · nonDerivative · entry 1 BARASCH RICHARD A · CIK 0001076341 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By LLC Disclosed balance after: 2,635,881 F1 · kind: RAB Ventures (DFP) LLC ("RAB Ventures") distributed 287,756 shares to one of its members, Boro Partners Fund 1 ("Boro") in accordance with Boro's beneficial interest in RAB Ventures. The reporting person is a 10% beneficial owner of Boro, but disclaims investment control over Boro. The reporting person disclaims beneficial ownership of these securities except to the extent of the reporting person's pecuniary interest therein. F2 · ownership.nature: The distributed shares were owned by RAB Ventures, an entity controlled by the reporting person. Read SEC document
June 18, 2025 Filed Jun 20, 2025 20:59 UTC	Starling Oncology, Inc. TOI · Entity 5327	ConversionClass A Common Equivalent Preferred Stock · Derivative	6,204	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001079973-25-001047 · ownership.xml · derivative · entry 4 BARASCH RICHARD A · CIK 0001076341 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 0 Underlying: Common Stock · 620,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Preferred Stock is convertible into 100 shares of Common Stock. No consideration was paid in connection with the conversion. F1 · kind: Represents the conversion of shares of Class A Common Equivalent Preferred Stock, par value $0.0001 (the "Preferred Stock") into shares of the Issuer's common stock, par value $0.0001 (the "Common Stock") in accordance with and pursuant to the Certificate of Designation of Preferences, Rights and Limitations of Series A Common Stock Equivalent Convertible Preferred Stock (the "Certificate of Designation"). F4 · derivative.exercise_date: Each share of Preferred Stock is convertible at any time at the option of the reporting person pursuant to the Certificate of Designation and has no expiration date. F4 · derivative.expiration_date: Each share of Preferred Stock is convertible at any time at the option of the reporting person pursuant to the Certificate of Designation and has no expiration date. F3 · ownership.nature: Securities are owned by Helen Barasch Family Trust #1, an affiliate of the reporting person. The reporting person disclaims beneficial ownership of these securities except to the extent of the reporting person's pecuniary interest therein. Read SEC document
June 18, 2025 Filed Jun 20, 2025 20:59 UTC	Starling Oncology, Inc. TOI · Entity 5327	ConversionCommon Stock	620,400	$0.00	$0.00	Disclosure SEC source: 0001079973-25-001047 · ownership.xml · nonDerivative · entry 2 BARASCH RICHARD A · CIK 0001076341 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 2,555,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion of shares of Class A Common Equivalent Preferred Stock, par value $0.0001 (the "Preferred Stock") into shares of the Issuer's common stock, par value $0.0001 (the "Common Stock") in accordance with and pursuant to the Certificate of Designation of Preferences, Rights and Limitations of Series A Common Stock Equivalent Convertible Preferred Stock (the "Certificate of Designation"). F2 · price: Each share of Preferred Stock is convertible into 100 shares of Common Stock. No consideration was paid in connection with the conversion. F3 · ownership.nature: Securities are owned by Helen Barasch Family Trust #1, an affiliate of the reporting person. The reporting person disclaims beneficial ownership of these securities except to the extent of the reporting person's pecuniary interest therein. Read SEC document
June 17, 2025 Filed Jun 20, 2025 20:59 UTC	Starling Oncology, Inc. TOI · Entity 5327	ConversionClass A Common Equivalent Preferred Stock · Derivative	1,595	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001079973-25-001047 · ownership.xml · derivative · entry 3 BARASCH RICHARD A · CIK 0001076341 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 159,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Preferred Stock is convertible into 100 shares of Common Stock. No consideration was paid in connection with the conversion. F1 · kind: Represents the conversion of shares of Class A Common Equivalent Preferred Stock, par value $0.0001 (the "Preferred Stock") into shares of the Issuer's common stock, par value $0.0001 (the "Common Stock") in accordance with and pursuant to the Certificate of Designation of Preferences, Rights and Limitations of Series A Common Stock Equivalent Convertible Preferred Stock (the "Certificate of Designation"). F4 · derivative.exercise_date: Each share of Preferred Stock is convertible at any time at the option of the reporting person pursuant to the Certificate of Designation and has no expiration date. F4 · derivative.expiration_date: Each share of Preferred Stock is convertible at any time at the option of the reporting person pursuant to the Certificate of Designation and has no expiration date. Read SEC document
June 17, 2025 Filed Jun 20, 2025 20:59 UTC	Starling Oncology, Inc. TOI · Entity 5327	ConversionCommon Stock	159,500	$0.00	$0.00	Disclosure SEC source: 0001079973-25-001047 · ownership.xml · nonDerivative · entry 1 BARASCH RICHARD A · CIK 0001076341 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,935,141 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion of shares of Class A Common Equivalent Preferred Stock, par value $0.0001 (the "Preferred Stock") into shares of the Issuer's common stock, par value $0.0001 (the "Common Stock") in accordance with and pursuant to the Certificate of Designation of Preferences, Rights and Limitations of Series A Common Stock Equivalent Convertible Preferred Stock (the "Certificate of Designation"). F2 · price: Each share of Preferred Stock is convertible into 100 shares of Common Stock. No consideration was paid in connection with the conversion. Read SEC document
June 17, 2025 Filed Jun 24, 2025 19:17 UTC	Starling Oncology, Inc. TOI · Entity 5327	OtherCommon Warrant · Derivative	679,224	$0.00 Strike: $1.20	$0.00	Disclosure SEC source: 0000935836-25-000435 · ownership.xml · derivative · entry 3 BARASCH RICHARD A · CIK 0001076341 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By LLC Disclosed balance after: 0 Underlying: Common Stock · 679,224 shares Expires 2030-03-26 F2 · kind: The exercise of the Common Warrant by RAB Ventures (DFP) LLC is exempt pursuant to Rule 16b-6. F4 · ownership.nature: Securities are owned by RAB Ventures (DFP) LLC, an entity controlled by the reporting person. The reporting person disclaims beneficial ownership of these securities except to the extent of the reporting person's pecuniary interest therein. Read SEC document
June 17, 2025 Filed Jun 24, 2025 19:17 UTC	Starling Oncology, Inc. TOI · Entity 5327	Tax withholdingCommon Stock	311,128	$2.62	$813,724.17	Disclosure SEC source: 0000935836-25-000435 · ownership.xml · nonDerivative · entry 2 BARASCH RICHARD A · CIK 0001076341 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By LLC Disclosed balance after: 2,923,637 F1 · kind: Represents the net exercise of a Common Stock Purchase Warrant ("Common Warrant") to purchase shares of common stock. The Common Warrant refers to such net exercise transaction as a "Cashless Exercise." In connection with the Cashless Exercise, the Issuer and RAB Ventures (DFP) LLC entered into a Waiver Agreement, pursuant to which the Issuer agreed to waive the Common Warrant provision restricting Cashless Exercises to circumstances where the resale of the underlying shares of common stock is not covered by an effective registration statement under the Securities Act of 1933, as amended. F3 · shares: RAB Ventures (DFP) LLC received 368,096 shares of common stock on a net exercise of the Common Warrant to purchase 679,224 shares of common stock. The Issuer withheld 311,128 shares of common stock underlying the Common Warrant for payment of the exercise price, using the fair market value of the common stock on the date of exercise, June 17, 2025, of $2.6154. The fair market value of the common stock was determined based on the average of the volume weighted average price on each of the five (5) consecutive trading days ending immediately prior to the date of exercise, pursuant to the terms of the Common Warrant. F4 · ownership.nature: Securities are owned by RAB Ventures (DFP) LLC, an entity controlled by the reporting person. The reporting person disclaims beneficial ownership of these securities except to the extent of the reporting person's pecuniary interest therein. Read SEC document
June 17, 2025 Filed Jun 24, 2025 19:17 UTC	Starling Oncology, Inc. TOI · Entity 5327	OtherCommon Stock	679,224	$1.20	$813,710.35	Disclosure SEC source: 0000935836-25-000435 · ownership.xml · nonDerivative · entry 1 BARASCH RICHARD A · CIK 0001076341 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By LLC Disclosed balance after: 3,234,765 F2 · kind: The exercise of the Common Warrant by RAB Ventures (DFP) LLC is exempt pursuant to Rule 16b-6. F4 · ownership.nature: Securities are owned by RAB Ventures (DFP) LLC, an entity controlled by the reporting person. The reporting person disclaims beneficial ownership of these securities except to the extent of the reporting person's pecuniary interest therein. Read SEC document
March 26, 2025 Filed Mar 28, 2025 17:25 UTC	Starling Oncology, Inc. TOI · Entity 5327	PurchaseCommon Warrant · Derivative	679,224	$0.13 Strike: $1.20	$84,903.00	Disclosure SEC source: 0001079973-25-000513 · ownership.xml · derivative · entry 2 BARASCH RICHARD A · CIK 0001076341 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By LLC Disclosed balance after: 679,224 Underlying: Common Stock · 679,224 shares Expires 2030-03-26 F1 · security: Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the "Private Placement"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued Private Placement units consisting of two shares of the Company's common stock ("Common Stock") and a common warrant ("Common Warrant") to purchase one share of Common Stock (the "Private Placement Unit"). F1 · kind: Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the "Private Placement"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued Private Placement units consisting of two shares of the Company's common stock ("Common Stock") and a common warrant ("Common Warrant") to purchase one share of Common Stock (the "Private Placement Unit"). F2 · price: Each Private Placement Unit was purchased at a price of $2.2084 per unit, with a cost per share of Common Stock of $1.0417 and a cost per Common Warrant of $0.1250. F4 · derivative.exercise_date: The holder may not exercise any portion of a Common Warrant to the extent that the holder would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately prior to or after giving effect to such exercise, as such percentage ownership is determined in accordance with Section 13(d) under the Securities Exchange Act of 1934, as amended. F3 · ownership.nature: Securities were purchased by RAB Ventures (DFP) LLC, an entity controlled by the reporting person. The reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein. Read SEC document
March 26, 2025 Filed Mar 28, 2025 17:25 UTC	Starling Oncology, Inc. TOI · Entity 5327	PurchaseCommon Stock	1,358,448	$1.04	$1,415,095.28	Disclosure SEC source: 0001079973-25-000513 · ownership.xml · nonDerivative · entry 1 BARASCH RICHARD A · CIK 0001076341 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By LLC Disclosed balance after: 1,775,641 F1 · kind: Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the "Private Placement"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued Private Placement units consisting of two shares of the Company's common stock ("Common Stock") and a common warrant ("Common Warrant") to purchase one share of Common Stock (the "Private Placement Unit"). F2 · price: Each Private Placement Unit was purchased at a price of $2.2084 per unit, with a cost per share of Common Stock of $1.0417 and a cost per Common Warrant of $0.1250. F3 · ownership.nature: Securities were purchased by RAB Ventures (DFP) LLC, an entity controlled by the reporting person. The reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein. Read SEC document
November 22, 2024 Filed Nov 25, 2024 16:38 UTC	Starling Oncology, Inc. TOI · Entity 5327	GrantCommon stock	80,000	$0.00	$0.00	Disclosure SEC source: 0001799191-24-000061 · wk-form4_1732570700.xml · nonDerivative · entry 1 BARASCH RICHARD A · CIK 0001076341 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 417,193 F1 · shares: Represents restricted stock units that vest in full on TOI, Inc.'s 2025 annual shareholder meeting date, subject to continued service with the Company through such vesting date. Read SEC document
June 18, 2024 Filed Jun 24, 2024 21:18 UTC	AdaptHealth Corp. AHCO · Entity 5183	Tax withholdingCommon Stock	3,559	$9.89	$35,198.51	Disclosure SEC source: 0001104659-24-074465 · tm2418148-1_4seq1.xml · nonDerivative · entry 1 BARASCH RICHARD A · CIK 0001076341 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 438,355 F1 · shares: The reporting person surrendered 3,559 shares to satisfy tax withholding liabilities in connection with the vesting of a previously issued restricted stock grant. Read SEC document
May 07, 2024 Filed May 9, 2024 18:21 UTC	AdaptHealth Corp. AHCO · Entity 5183	Tax withholdingCommon Stock	8,547	$9.85	$84,187.95	Disclosure SEC source: 0001104659-24-059489 · tm2413346-2_4seq1.xml · nonDerivative · entry 1 BARASCH RICHARD A · CIK 0001076341 · Director · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 441,914 F1 · shares: The reporting person surrendered 8,547 shares to satisfy tax withholding liabilities in connection with the vesting of a previously issued restricted stock grant. Read SEC document
April 30, 2024 Filed May 2, 2024 16:41 UTC	AdaptHealth Corp. AHCO · Entity 5183	GrantCommon Stock	8,829	$0.00	$0.00	Disclosure SEC source: 0001104659-24-056426 · tm2413346-1_4seq1.xml · nonDerivative · entry 1 BARASCH RICHARD A · CIK 0001076341 · Director · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 450,461 F1 · shares: Represents a grant of restricted stock units, 100% of which will vest immediately on May 19, 2024. F2 · balance_after: This figure reflects a gift previously made by the reporting person, as disclosed in a Form 5 filed on April 8, 2024. Read SEC document
March 02, 2024 Filed Mar 4, 2024 19:14 UTC	AdaptHealth Corp. AHCO · Entity 5183	GrantCommon Stock	21,206	$0.00	$0.00	Disclosure SEC source: 0001104659-24-030617 · tm247884-1_4seq1.xml · nonDerivative · entry 2 BARASCH RICHARD A · CIK 0001076341 · Director · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 451,632 F2 · shares: Represents a grant of restricted stock units, 100% of which will vest immediately on April 30, 2024. Read SEC document
February 29, 2024 Filed Mar 4, 2024 19:14 UTC	AdaptHealth Corp. AHCO · Entity 5183	Tax withholdingCommon Stock	8,984	$10.23	$91,906.32	Disclosure SEC source: 0001104659-24-030617 · tm247884-1_4seq1.xml · nonDerivative · entry 1 BARASCH RICHARD A · CIK 0001076341 · Director · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 430,426 F1 · shares: The reporting person surrendered 8,984 shares to satisfy tax withholding liabilities in connection with the vesting of a previously issued restricted stock grant. Read SEC document
January 02, 2024 Filed Jan 3, 2024 16:29 UTC	AdaptHealth Corp. AHCO · Entity 5183	Tax withholdingCommon Stock	9,226	$7.26	$66,980.76	Disclosure SEC source: 0001104659-24-000857 · tm241613-1_4seq1.xml · nonDerivative · entry 2 BARASCH RICHARD A · CIK 0001076341 · Director · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 439,410 F2 · shares: The reporting person surrendered 9,226 shares to satisfy tax withholding liabilities in connection with the vesting of a previously issued restricted stock grant. Read SEC document
December 29, 2023 Filed Jan 3, 2024 16:29 UTC	AdaptHealth Corp. AHCO · Entity 5183	GrantCommon Stock	22,291	$0.00	$0.00	Disclosure SEC source: 0001104659-24-000857 · tm241613-1_4seq1.xml · nonDerivative · entry 1 BARASCH RICHARD A · CIK 0001076341 · Director · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 448,636 F1 · shares: Represents a grant of restricted stock units, 100% of which will vest immediately on February 29, 2024. Read SEC document
December 26, 2023 Filed Dec 28, 2023 17:58 UTC	Starling Oncology, Inc. TOI · Entity 5327	GrantCommon stock	80,000	$0.00	$0.00	Disclosure SEC source: 0001628280-23-042830 · wk-form4_1703804321.xml · nonDerivative · entry 1 BARASCH RICHARD A · CIK 0001076341 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 337,193 F1 · price: Represents restricted stock units that vest in full on TOI, Inc. 2024 annual shareholder meeting date, subject to continued service with the Company through such vesting date. Read SEC document
October 31, 2023 Filed Nov 2, 2023 17:37 UTC	AdaptHealth Corp. AHCO · Entity 5183	GrantCommon Stock	22,891	$0.00	$0.00	Disclosure SEC source: 0001104659-23-113878 · tm2329711-1_4seq1.xml · nonDerivative · entry 1 BARASCH RICHARD A · CIK 0001076341 · Director · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 426,345 F1 · shares: Represents a grant of restricted stock units, 100% of which will vest immediately on December 31, 2023. Read SEC document
August 31, 2023 Filed Sep 5, 2023 20:05 UTC	AdaptHealth Corp. AHCO · Entity 5183	GrantCommon Stock	13,698	$0.00	$0.00	Disclosure SEC source: 0001104659-23-098420 · tm2325500-1_4seq1.xml · nonDerivative · entry 2 BARASCH RICHARD A · CIK 0001076341 · Director · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 403,454 F2 · shares: Represents a grant of restricted stock units, 100% of which will vest immediately on October 31, 2023. Read SEC document
August 31, 2023 Filed Sep 5, 2023 20:05 UTC	AdaptHealth Corp. AHCO · Entity 5183	Tax withholdingCommon Stock	6,908	$11.93	$82,412.44	Disclosure SEC source: 0001104659-23-098420 · tm2325500-1_4seq1.xml · nonDerivative · entry 1 BARASCH RICHARD A · CIK 0001076341 · Director · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 389,756 F1 · shares: The reporting person surrendered 6,908 shares to satisfy tax withholding liabilities in connection with the vesting of a previously issued restricted stock grant. Read SEC document
June 26, 2023 Filed Aug 14, 2023 19:01 UTC	AdaptHealth Corp. AHCO · Entity 5183	GrantCommon Stock	17,143	$0.00	$0.00	Disclosure SEC source: 0001104659-23-091574 · tm2323660-3_4seq1.xml · nonDerivative · entry 1 BARASCH RICHARD A · CIK 0001076341 · Director · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 396,664 F1 · shares: Represents a grant of restricted stock, 100% of which will vest immediately on August 31, 2023. Read SEC document
June 22, 2023 Filed Jun 26, 2023 21:06 UTC	AdaptHealth Corp. AHCO · Entity 5183	GrantCommon Stock	25,614	$0.00	$0.00	Disclosure SEC source: 0001104659-23-074905 · tm2319712-8_4seq1.xml · nonDerivative · entry 1 BARASCH RICHARD A · CIK 0001076341 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 379,521 Read SEC document
March 17, 2023 Filed Mar 21, 2023 21:01 UTC	Starling Oncology, Inc. TOI · Entity 5327	PurchaseCommon stock	10,000	$0.55	$5,500.00	Disclosure SEC source: 0001628280-23-008836 · wf-form4_167944686729240.xml · nonDerivative · entry 8 BARASCH RICHARD A · CIK 0001076341 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 257,193 Read SEC document
March 17, 2023 Filed Mar 21, 2023 21:01 UTC	Starling Oncology, Inc. TOI · Entity 5327	PurchaseCommon stock	10,000	$0.55	$5,500.00	Disclosure SEC source: 0001628280-23-008836 · wf-form4_167944686729240.xml · nonDerivative · entry 7 BARASCH RICHARD A · CIK 0001076341 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 247,193 Read SEC document
March 17, 2023 Filed Mar 21, 2023 21:01 UTC	Starling Oncology, Inc. TOI · Entity 5327	PurchaseCommon stock	2,146	$0.55	$1,176.01	Disclosure SEC source: 0001628280-23-008836 · wf-form4_167944686729240.xml · nonDerivative · entry 6 BARASCH RICHARD A · CIK 0001076341 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 237,193 Read SEC document
March 17, 2023 Filed Mar 21, 2023 21:01 UTC	Starling Oncology, Inc. TOI · Entity 5327	PurchaseCommon stock	7,654	$0.55	$4,209.70	Disclosure SEC source: 0001628280-23-008836 · wf-form4_167944686729240.xml · nonDerivative · entry 5 BARASCH RICHARD A · CIK 0001076341 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 235,047 Read SEC document
March 17, 2023 Filed Mar 21, 2023 21:01 UTC	Starling Oncology, Inc. TOI · Entity 5327	PurchaseCommon stock	9,948	$0.55	$5,471.40	Disclosure SEC source: 0001628280-23-008836 · wf-form4_167944686729240.xml · nonDerivative · entry 4 BARASCH RICHARD A · CIK 0001076341 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 227,393 Read SEC document
March 17, 2023 Filed Mar 21, 2023 21:01 UTC	Starling Oncology, Inc. TOI · Entity 5327	PurchaseCommon stock	200	$0.55	$109.60	Disclosure SEC source: 0001628280-23-008836 · wf-form4_167944686729240.xml · nonDerivative · entry 3 BARASCH RICHARD A · CIK 0001076341 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217,445 Read SEC document
March 17, 2023 Filed Mar 21, 2023 21:01 UTC	Starling Oncology, Inc. TOI · Entity 5327	PurchaseCommon stock	52	$0.55	$28.55	Disclosure SEC source: 0001628280-23-008836 · wf-form4_167944686729240.xml · nonDerivative · entry 2 BARASCH RICHARD A · CIK 0001076341 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217,245 Read SEC document
March 17, 2023 Filed Mar 21, 2023 21:01 UTC	Starling Oncology, Inc. TOI · Entity 5327	PurchaseCommon stock	10,000	$0.55	$5,500.00	Disclosure SEC source: 0001628280-23-008836 · wf-form4_167944686729240.xml · nonDerivative · entry 1 BARASCH RICHARD A · CIK 0001076341 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217,193 Read SEC document
November 18, 2022 Filed Apr 8, 2024 16:28 UTC	AdaptHealth Corp. AHCO · Entity 5183	GiftCommon Stock	10,000	$0.00	$0.00	Disclosure SEC source: 0001104659-24-044758 · tm2411299-1_5seq1.xml · nonDerivative · entry 1 BARASCH RICHARD A · CIK 0001076341 · Director · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 343,907 F1 · kind: The reported transaction represents a gift/charitable donation of securities totaling 10,000 shares of the issuer's Common Stock to National Philanthropic Trust, a Pennsylvania non-profit corporation, to be held in a donor-advised fund. Read SEC document
November 17, 2022 Filed Nov 21, 2022 17:31 UTC	Starling Oncology, Inc. TOI · Entity 5327	GrantCommon Stock	22,708	$0.00	$0.00	Disclosure SEC source: 0001799191-22-000031 · edgardoc.xml · nonDerivative · entry 1 BARASCH RICHARD A · CIK 0001076341 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,727 F1 · price: Represents restricted stock units that vest in full on May 17, 2023, subject to continued service with the Company through such vesting date. Read SEC document
November 17, 2022 Filed Dec 30, 2022 16:38 UTC Amendment	Starling Oncology, Inc. TOI · Entity 5327	GrantCommon Stock	65,174	$0.00	$0.00	Disclosure SEC source: 0001799191-22-000060 · edgardoc.xml · nonDerivative · entry 1 BARASCH RICHARD A · CIK 0001076341 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,193 F1 · shares: This amendment is filed to correct the number of restricted stock units granted due to an administrative error in applying the grant amount calculations. F2 · price: Represents restricted stock units that vest in full on May 17, 2023, subject to continued service with the Company through such vesting date. Read SEC document
October 05, 2022 Filed Oct 7, 2022 16:48 UTC	Starling Oncology, Inc. TOI · Entity 5327	OtherEarnout rights (Private placement warrants) · Derivative	73,024	Not disclosed Strike: $11.50	Not disclosed	Disclosure SEC source: 0001628280-22-026163 · wf-form4_166517567146567.xml · derivative · entry 8 BARASCH RICHARD A · CIK 0001076341 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,024 Underlying: Common stock · 73,024 shares Expires not disclosed F6 · security: Represents Private Placement Warrants held in escrow, (i) 50% of which shall be released from escrow in the event the issuer's stock price equals or exceeds $12.50 per share for 20 days within any 30 consecutive trading days during the two-year period ending on November 12, 2023, and (ii) the remainder of which shall be released from escrow in the event the issuer's stock price equals or exceeds $15.00 per share for any 20 trading days within any 30-day trading period during the three-year period ending November 12, 2024. Notwithstanding the forgoing, all warrants shall be released from escrow in the event of a qualifying change of control. F6 · derivative.exercise_price: Represents Private Placement Warrants held in escrow, (i) 50% of which shall be released from escrow in the event the issuer's stock price equals or exceeds $12.50 per share for 20 days within any 30 consecutive trading days during the two-year period ending on November 12, 2023, and (ii) the remainder of which shall be released from escrow in the event the issuer's stock price equals or exceeds $15.00 per share for any 20 trading days within any 30-day trading period during the three-year period ending November 12, 2024. Notwithstanding the forgoing, all warrants shall be released from escrow in the event of a qualifying change of control. F1 · kind: Represents securities received in distributions to LLC members, on a pro rata basis for no consideration, in exempt transactions under Rule 16a-9. F1 · price: Represents securities received in distributions to LLC members, on a pro rata basis for no consideration, in exempt transactions under Rule 16a-9. F5 · derivative.exercise_date: Each whole private placement warrant (the "Private Placement Warrant") entitles the holder thereof to purchase one share of the issuer's common stock at an exercise price of $11.50 per share. The warrants are currently exercisable and will expire on November 12, 2026 or earlier upon redemption or liquidation. F6 · derivative.exercise_date: Represents Private Placement Warrants held in escrow, (i) 50% of which shall be released from escrow in the event the issuer's stock price equals or exceeds $12.50 per share for 20 days within any 30 consecutive trading days during the two-year period ending on November 12, 2023, and (ii) the remainder of which shall be released from escrow in the event the issuer's stock price equals or exceeds $15.00 per share for any 20 trading days within any 30-day trading period during the three-year period ending November 12, 2024. Notwithstanding the forgoing, all warrants shall be released from escrow in the event of a qualifying change of control. F5 · derivative.expiration_date: Each whole private placement warrant (the "Private Placement Warrant") entitles the holder thereof to purchase one share of the issuer's common stock at an exercise price of $11.50 per share. The warrants are currently exercisable and will expire on November 12, 2026 or earlier upon redemption or liquidation. F6 · derivative.expiration_date: Represents Private Placement Warrants held in escrow, (i) 50% of which shall be released from escrow in the event the issuer's stock price equals or exceeds $12.50 per share for 20 days within any 30 consecutive trading days during the two-year period ending on November 12, 2023, and (ii) the remainder of which shall be released from escrow in the event the issuer's stock price equals or exceeds $15.00 per share for any 20 trading days within any 30-day trading period during the three-year period ending November 12, 2024. Notwithstanding the forgoing, all warrants shall be released from escrow in the event of a qualifying change of control. Read SEC document
October 05, 2022 Filed Oct 7, 2022 16:48 UTC	Starling Oncology, Inc. TOI · Entity 5327	OtherPrivate Placement Warrants · Derivative	548,503	Not disclosed Strike: $11.50	Not disclosed	Disclosure SEC source: 0001628280-22-026163 · wf-form4_166517567146567.xml · derivative · entry 7 BARASCH RICHARD A · CIK 0001076341 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 548,503 Underlying: Common stock · 548,503 shares Expires not disclosed F5 · security: Each whole private placement warrant (the "Private Placement Warrant") entitles the holder thereof to purchase one share of the issuer's common stock at an exercise price of $11.50 per share. The warrants are currently exercisable and will expire on November 12, 2026 or earlier upon redemption or liquidation. F5 · derivative.exercise_price: Each whole private placement warrant (the "Private Placement Warrant") entitles the holder thereof to purchase one share of the issuer's common stock at an exercise price of $11.50 per share. The warrants are currently exercisable and will expire on November 12, 2026 or earlier upon redemption or liquidation. F1 · kind: Represents securities received in distributions to LLC members, on a pro rata basis for no consideration, in exempt transactions under Rule 16a-9. F1 · price: Represents securities received in distributions to LLC members, on a pro rata basis for no consideration, in exempt transactions under Rule 16a-9. F5 · derivative.exercise_date: Each whole private placement warrant (the "Private Placement Warrant") entitles the holder thereof to purchase one share of the issuer's common stock at an exercise price of $11.50 per share. The warrants are currently exercisable and will expire on November 12, 2026 or earlier upon redemption or liquidation. F5 · derivative.expiration_date: Each whole private placement warrant (the "Private Placement Warrant") entitles the holder thereof to purchase one share of the issuer's common stock at an exercise price of $11.50 per share. The warrants are currently exercisable and will expire on November 12, 2026 or earlier upon redemption or liquidation. Read SEC document
October 05, 2022 Filed Oct 7, 2022 16:48 UTC	Starling Oncology, Inc. TOI · Entity 5327	OtherEarnout rights (Series A Common Stock Equiv Conv Preferred) · Derivative	894	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-22-026163 · wf-form4_166517567146567.xml · derivative · entry 6 BARASCH RICHARD A · CIK 0001076341 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust Disclosed balance after: 894 Underlying: Common stock · 89,400 shares Expires not disclosed F4 · security: Represents shares of Common Equivalent Preferred Stock held in escrow, (i) 50% of which shall be released from escrow in the event the issuer's stock price equals or exceeds $12.50 per share for 20 days within any 30 consecutive trading days during the two-year period ending on November 12, 2023, and (ii) the remainder of which shall be released from escrow in the event the issuer's stock price equals or exceeds $15.00 per share for any 20 trading days within any 30-day trading period during the three-year period ending November 12, 2024. Notwithstanding the forgoing, all shares shall be released from escrow in the event of a qualifying change of control. F4 · derivative.exercise_price: Represents shares of Common Equivalent Preferred Stock held in escrow, (i) 50% of which shall be released from escrow in the event the issuer's stock price equals or exceeds $12.50 per share for 20 days within any 30 consecutive trading days during the two-year period ending on November 12, 2023, and (ii) the remainder of which shall be released from escrow in the event the issuer's stock price equals or exceeds $15.00 per share for any 20 trading days within any 30-day trading period during the three-year period ending November 12, 2024. Notwithstanding the forgoing, all shares shall be released from escrow in the event of a qualifying change of control. F1 · kind: Represents securities received in distributions to LLC members, on a pro rata basis for no consideration, in exempt transactions under Rule 16a-9. F1 · price: Represents securities received in distributions to LLC members, on a pro rata basis for no consideration, in exempt transactions under Rule 16a-9. F4 · derivative.exercise_date: Represents shares of Common Equivalent Preferred Stock held in escrow, (i) 50% of which shall be released from escrow in the event the issuer's stock price equals or exceeds $12.50 per share for 20 days within any 30 consecutive trading days during the two-year period ending on November 12, 2023, and (ii) the remainder of which shall be released from escrow in the event the issuer's stock price equals or exceeds $15.00 per share for any 20 trading days within any 30-day trading period during the three-year period ending November 12, 2024. Notwithstanding the forgoing, all shares shall be released from escrow in the event of a qualifying change of control. F4 · derivative.expiration_date: Represents shares of Common Equivalent Preferred Stock held in escrow, (i) 50% of which shall be released from escrow in the event the issuer's stock price equals or exceeds $12.50 per share for 20 days within any 30 consecutive trading days during the two-year period ending on November 12, 2023, and (ii) the remainder of which shall be released from escrow in the event the issuer's stock price equals or exceeds $15.00 per share for any 20 trading days within any 30-day trading period during the three-year period ending November 12, 2024. Notwithstanding the forgoing, all shares shall be released from escrow in the event of a qualifying change of control. F2 · ownership.nature: Securities held by the Helen Barasch Family Trust #1 (the "Trust"), of which the reporting person is the investment manager and has voting and dispositive power over the securities held by the Trust, but disclaims beneficial ownership of these shares except to any pecuniary interest therein. Read SEC document
October 05, 2022 Filed Oct 7, 2022 16:48 UTC	Starling Oncology, Inc. TOI · Entity 5327	OtherSeries A Common Stock Equivalent Convertible Preferred Stock · Derivative	6,204	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-22-026163 · wf-form4_166517567146567.xml · derivative · entry 5 BARASCH RICHARD A · CIK 0001076341 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust Disclosed balance after: 6,204 Underlying: Common stock · 620,400 shares Expires not disclosed F3 · security: Each share of Series A Common Stock Equivalent Convertible Preferred Stock ("Common Equivalent Preferred Stock") is convertible into 100 shares of common stock (subject to adjustment) at any time and from time to time at the election of the holder thereof. The Common Equivalent Preferred Stock has no expiration date. The terms of the Common Equivalent Preferred Stock restrict the conversion of such shares to the extent that, upon such conversion, the number of shares of Class A Common Stock then beneficially owned by the holder and its affiliates and any other person or entities with which such holder would constitute a Section 13(d) "group" would exceed 4.9% of the total number of shares of Class A Common Stock then outstanding. F3 · derivative.exercise_price: Each share of Series A Common Stock Equivalent Convertible Preferred Stock ("Common Equivalent Preferred Stock") is convertible into 100 shares of common stock (subject to adjustment) at any time and from time to time at the election of the holder thereof. The Common Equivalent Preferred Stock has no expiration date. The terms of the Common Equivalent Preferred Stock restrict the conversion of such shares to the extent that, upon such conversion, the number of shares of Class A Common Stock then beneficially owned by the holder and its affiliates and any other person or entities with which such holder would constitute a Section 13(d) "group" would exceed 4.9% of the total number of shares of Class A Common Stock then outstanding. F1 · kind: Represents securities received in distributions to LLC members, on a pro rata basis for no consideration, in exempt transactions under Rule 16a-9. F1 · price: Represents securities received in distributions to LLC members, on a pro rata basis for no consideration, in exempt transactions under Rule 16a-9. F3 · derivative.exercise_date: Each share of Series A Common Stock Equivalent Convertible Preferred Stock ("Common Equivalent Preferred Stock") is convertible into 100 shares of common stock (subject to adjustment) at any time and from time to time at the election of the holder thereof. The Common Equivalent Preferred Stock has no expiration date. The terms of the Common Equivalent Preferred Stock restrict the conversion of such shares to the extent that, upon such conversion, the number of shares of Class A Common Stock then beneficially owned by the holder and its affiliates and any other person or entities with which such holder would constitute a Section 13(d) "group" would exceed 4.9% of the total number of shares of Class A Common Stock then outstanding. F3 · derivative.expiration_date: Each share of Series A Common Stock Equivalent Convertible Preferred Stock ("Common Equivalent Preferred Stock") is convertible into 100 shares of common stock (subject to adjustment) at any time and from time to time at the election of the holder thereof. The Common Equivalent Preferred Stock has no expiration date. The terms of the Common Equivalent Preferred Stock restrict the conversion of such shares to the extent that, upon such conversion, the number of shares of Class A Common Stock then beneficially owned by the holder and its affiliates and any other person or entities with which such holder would constitute a Section 13(d) "group" would exceed 4.9% of the total number of shares of Class A Common Stock then outstanding. F2 · ownership.nature: Securities held by the Helen Barasch Family Trust #1 (the "Trust"), of which the reporting person is the investment manager and has voting and dispositive power over the securities held by the Trust, but disclaims beneficial ownership of these shares except to any pecuniary interest therein. Read SEC document
October 05, 2022 Filed Oct 7, 2022 16:48 UTC	Starling Oncology, Inc. TOI · Entity 5327	OtherEarnout rights (Series A Common Stock Equiv Conv Preferred) · Derivative	230	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-22-026163 · wf-form4_166517567146567.xml · derivative · entry 4 BARASCH RICHARD A · CIK 0001076341 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230 Underlying: Common stock · 23,000 shares Expires not disclosed F4 · security: Represents shares of Common Equivalent Preferred Stock held in escrow, (i) 50% of which shall be released from escrow in the event the issuer's stock price equals or exceeds $12.50 per share for 20 days within any 30 consecutive trading days during the two-year period ending on November 12, 2023, and (ii) the remainder of which shall be released from escrow in the event the issuer's stock price equals or exceeds $15.00 per share for any 20 trading days within any 30-day trading period during the three-year period ending November 12, 2024. Notwithstanding the forgoing, all shares shall be released from escrow in the event of a qualifying change of control. F4 · derivative.exercise_price: Represents shares of Common Equivalent Preferred Stock held in escrow, (i) 50% of which shall be released from escrow in the event the issuer's stock price equals or exceeds $12.50 per share for 20 days within any 30 consecutive trading days during the two-year period ending on November 12, 2023, and (ii) the remainder of which shall be released from escrow in the event the issuer's stock price equals or exceeds $15.00 per share for any 20 trading days within any 30-day trading period during the three-year period ending November 12, 2024. Notwithstanding the forgoing, all shares shall be released from escrow in the event of a qualifying change of control. F1 · kind: Represents securities received in distributions to LLC members, on a pro rata basis for no consideration, in exempt transactions under Rule 16a-9. F1 · price: Represents securities received in distributions to LLC members, on a pro rata basis for no consideration, in exempt transactions under Rule 16a-9. F4 · derivative.exercise_date: Represents shares of Common Equivalent Preferred Stock held in escrow, (i) 50% of which shall be released from escrow in the event the issuer's stock price equals or exceeds $12.50 per share for 20 days within any 30 consecutive trading days during the two-year period ending on November 12, 2023, and (ii) the remainder of which shall be released from escrow in the event the issuer's stock price equals or exceeds $15.00 per share for any 20 trading days within any 30-day trading period during the three-year period ending November 12, 2024. Notwithstanding the forgoing, all shares shall be released from escrow in the event of a qualifying change of control. F4 · derivative.expiration_date: Represents shares of Common Equivalent Preferred Stock held in escrow, (i) 50% of which shall be released from escrow in the event the issuer's stock price equals or exceeds $12.50 per share for 20 days within any 30 consecutive trading days during the two-year period ending on November 12, 2023, and (ii) the remainder of which shall be released from escrow in the event the issuer's stock price equals or exceeds $15.00 per share for any 20 trading days within any 30-day trading period during the three-year period ending November 12, 2024. Notwithstanding the forgoing, all shares shall be released from escrow in the event of a qualifying change of control. Read SEC document
October 05, 2022 Filed Oct 7, 2022 16:48 UTC	Starling Oncology, Inc. TOI · Entity 5327	OtherSeries A Common Stock Equivalent Convertible Preferred Stock · Derivative	1,595	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-22-026163 · wf-form4_166517567146567.xml · derivative · entry 3 BARASCH RICHARD A · CIK 0001076341 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,595 Underlying: Common stock · 159,500 shares Expires not disclosed F3 · security: Each share of Series A Common Stock Equivalent Convertible Preferred Stock ("Common Equivalent Preferred Stock") is convertible into 100 shares of common stock (subject to adjustment) at any time and from time to time at the election of the holder thereof. The Common Equivalent Preferred Stock has no expiration date. The terms of the Common Equivalent Preferred Stock restrict the conversion of such shares to the extent that, upon such conversion, the number of shares of Class A Common Stock then beneficially owned by the holder and its affiliates and any other person or entities with which such holder would constitute a Section 13(d) "group" would exceed 4.9% of the total number of shares of Class A Common Stock then outstanding. F3 · derivative.exercise_price: Each share of Series A Common Stock Equivalent Convertible Preferred Stock ("Common Equivalent Preferred Stock") is convertible into 100 shares of common stock (subject to adjustment) at any time and from time to time at the election of the holder thereof. The Common Equivalent Preferred Stock has no expiration date. The terms of the Common Equivalent Preferred Stock restrict the conversion of such shares to the extent that, upon such conversion, the number of shares of Class A Common Stock then beneficially owned by the holder and its affiliates and any other person or entities with which such holder would constitute a Section 13(d) "group" would exceed 4.9% of the total number of shares of Class A Common Stock then outstanding. F1 · kind: Represents securities received in distributions to LLC members, on a pro rata basis for no consideration, in exempt transactions under Rule 16a-9. F1 · price: Represents securities received in distributions to LLC members, on a pro rata basis for no consideration, in exempt transactions under Rule 16a-9. F3 · derivative.exercise_date: Each share of Series A Common Stock Equivalent Convertible Preferred Stock ("Common Equivalent Preferred Stock") is convertible into 100 shares of common stock (subject to adjustment) at any time and from time to time at the election of the holder thereof. The Common Equivalent Preferred Stock has no expiration date. The terms of the Common Equivalent Preferred Stock restrict the conversion of such shares to the extent that, upon such conversion, the number of shares of Class A Common Stock then beneficially owned by the holder and its affiliates and any other person or entities with which such holder would constitute a Section 13(d) "group" would exceed 4.9% of the total number of shares of Class A Common Stock then outstanding. F3 · derivative.expiration_date: Each share of Series A Common Stock Equivalent Convertible Preferred Stock ("Common Equivalent Preferred Stock") is convertible into 100 shares of common stock (subject to adjustment) at any time and from time to time at the election of the holder thereof. The Common Equivalent Preferred Stock has no expiration date. The terms of the Common Equivalent Preferred Stock restrict the conversion of such shares to the extent that, upon such conversion, the number of shares of Class A Common Stock then beneficially owned by the holder and its affiliates and any other person or entities with which such holder would constitute a Section 13(d) "group" would exceed 4.9% of the total number of shares of Class A Common Stock then outstanding. Read SEC document
October 05, 2022 Filed Oct 7, 2022 16:48 UTC	Starling Oncology, Inc. TOI · Entity 5327	OtherCommon stock	8	$0.00	$0.00	Disclosure SEC source: 0001628280-22-026163 · wf-form4_166517567146567.xml · nonDerivative · entry 2 BARASCH RICHARD A · CIK 0001076341 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust Disclosed balance after: 8 F1 · kind: Represents securities received in distributions to LLC members, on a pro rata basis for no consideration, in exempt transactions under Rule 16a-9. F1 · price: Represents securities received in distributions to LLC members, on a pro rata basis for no consideration, in exempt transactions under Rule 16a-9. F2 · ownership.nature: Securities held by the Helen Barasch Family Trust #1 (the "Trust"), of which the reporting person is the investment manager and has voting and dispositive power over the securities held by the Trust, but disclaims beneficial ownership of these shares except to any pecuniary interest therein. Read SEC document
October 05, 2022 Filed Oct 7, 2022 16:48 UTC	Starling Oncology, Inc. TOI · Entity 5327	OtherCommon stock	1	$0.00	$0.00	Disclosure SEC source: 0001628280-22-026163 · wf-form4_166517567146567.xml · nonDerivative · entry 1 BARASCH RICHARD A · CIK 0001076341 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,019 F1 · kind: Represents securities received in distributions to LLC members, on a pro rata basis for no consideration, in exempt transactions under Rule 16a-9. F1 · price: Represents securities received in distributions to LLC members, on a pro rata basis for no consideration, in exempt transactions under Rule 16a-9. Read SEC document
June 22, 2022 Filed Jun 24, 2022 16:26 UTC	AdaptHealth Corp. AHCO · Entity 5183	GrantCommon Stock	14,970	$0.00	$0.00	Disclosure SEC source: 0001104659-22-074326 · tm2219351-3_4seq1.xml · nonDerivative · entry 1 BARASCH RICHARD A · CIK 0001076341 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,907 Read SEC document
March 21, 2022 Filed Mar 23, 2022 19:34 UTC	Starling Oncology, Inc. TOI · Entity 5327	GrantCommon stock	45,905	$0.00	$0.00	Disclosure SEC source: 0001628280-22-007094 · wf-form4_164807845002324.xml · nonDerivative · entry 1 BARASCH RICHARD A · CIK 0001076341 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,018 F1 · shares: Represents restricted stock units that vest in full on November 12, 2022, subject to continued service with the Company through such vesting date. F1 · price: Represents restricted stock units that vest in full on November 12, 2022, subject to continued service with the Company through such vesting date. Read SEC document
November 24, 2021 Filed Nov 24, 2021 18:01 UTC	Starling Oncology, Inc. TOI · Entity 5327	PurchaseCommon Stock	1,200	$7.20	$8,642.64	Disclosure SEC source: 0001104659-21-143688 · tm2133957-1_4seq1.xml · nonDerivative · entry 3 BARASCH RICHARD A · CIK 0001076341 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,113 Read SEC document
November 24, 2021 Filed Nov 24, 2021 18:01 UTC	Starling Oncology, Inc. TOI · Entity 5327	PurchaseCommon Stock	1,800	$6.86	$12,344.40	Disclosure SEC source: 0001104659-21-143688 · tm2133957-1_4seq1.xml · nonDerivative · entry 2 BARASCH RICHARD A · CIK 0001076341 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,913 Read SEC document
November 24, 2021 Filed Nov 24, 2021 18:01 UTC	Starling Oncology, Inc. TOI · Entity 5327	PurchaseCommon Stock	2,000	$6.81	$13,617.60	Disclosure SEC source: 0001104659-21-143688 · tm2133957-1_4seq1.xml · nonDerivative · entry 1 BARASCH RICHARD A · CIK 0001076341 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,113 Read SEC document
November 23, 2021 Filed Nov 24, 2021 06:01 UTC	Starling Oncology, Inc. TOI · Entity 5327	PurchaseCommon Stock	4,500	$6.35	$28,566.00	Disclosure SEC source: 0001104659-21-143245 · tm2133425d7_4seq1.xml · nonDerivative · entry 2 BARASCH RICHARD A · CIK 0001076341 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,113 Read SEC document
November 23, 2021 Filed Nov 24, 2021 06:01 UTC	Starling Oncology, Inc. TOI · Entity 5327	PurchaseCommon Stock	500	$6.27	$3,133.35	Disclosure SEC source: 0001104659-21-143245 · tm2133425d7_4seq1.xml · nonDerivative · entry 1 BARASCH RICHARD A · CIK 0001076341 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,613 Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.